Deciphering the Combinatorial Landscape of Immunity
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Metallothionein Monoclonal Antibody, Clone N11-G
Metallothionein monoclonal antibody, clone N11-G Catalog # : MAB9787 規格 : [ 50 uL ] List All Specification Application Image Product Rabbit monoclonal antibody raised against synthetic peptide of MT1A, Western Blot (Recombinant protein) Description: MT1B, MT1E, MT1F, MT1G, MT1H, MT1IP, MT1L, MT1M, MT2A. Immunogen: A synthetic peptide corresponding to N-terminus of human MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1IP, MT1L, MT1M, MT2A. Host: Rabbit enlarge Reactivity: Human, Mouse Immunoprecipitation Form: Liquid Enzyme-linked Immunoabsorbent Assay Recommend Western Blot (1:1000) Usage: ELISA (1:5000-1:10000) The optimal working dilution should be determined by the end user. Storage Buffer: In 20 mM Tris-HCl, pH 8.0 (10 mg/mL BSA, 0.05% sodium azide) Storage Store at -20°C. Instruction: Note: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. Datasheet: Download Applications Western Blot (Recombinant protein) Western blot analysis of recombinant Metallothionein protein with Metallothionein monoclonal antibody, clone N11-G (Cat # MAB9787). Lane 1: 1 ug. Lane 2: 3 ug. Lane 3: 5 ug. Immunoprecipitation Enzyme-linked Immunoabsorbent Assay ASSP5 MT1A MT1B MT1E MT1F MT1G MT1H MT1M MT1L MT1IP Page 1 of 5 2021/6/2 Gene Information Entrez GeneID: 4489 Protein P04731 (Gene ID : 4489);P07438 (Gene ID : 4490);P04732 (Gene ID : Accession#: 4493);P04733 (Gene ID : 4494);P13640 (Gene ID : 4495);P80294 (Gene ID : 4496);P80295 (Gene ID : 4496);Q8N339 (Gene ID : 4499);Q86YX0 (Gene ID : 4490);Q86YX5 -
Identification of 10 Hub Genes Related to the Progression of Colorectal
Identification of 10 Hub genes related to the progression of colorectal cancer by co-expression analysis Jie Meng1,2, Rui Su2, Yun Liao2, Yanyan Li2 and Ling Li2 1 Department of Pharmacy, Anhui University of Chinese Medicine, Hefei, China 2 Department of Pharmacy, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China ABSTRACT Background: Colorectal cancer (CRC) is the third most common cancer in the world. The present study is aimed at identifying hub genes associated with the progression of CRC. Method: The data of the patients with CRC were obtained from the Gene Expression Omnibus (GEO) database and assessed by weighted gene co-expression network analysis (WGCNA), Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses performed in R by WGCNA, several hub genes that regulate the mechanism of tumorigenesis in CRC were identified. Differentially expressed genes in the data sets GSE28000 and GSE42284 were used to construct a co-expression network for WGCNA. The yellow, black and blue modules associated with CRC level were filtered. Combining the co-expression network and the PPI network, 15 candidate hub genes were screened. Results: After validation using the TCGA-COAD dataset, a total of 10 hub genes (MT1X, MT1G, MT2A, CXCL8, IL1B, CXCL5, CXCL11, IL10RA, GZMB, KIT) closely related to the progression of CRC were identified. The expressions of MT1G, CXCL8, IL1B, CXCL5, CXCL11 and GZMB in CRC tissues were higher than normal tissues (p-value < 0.05). The expressions of MT1X, MT2A, IL10RA and KIT in CRC tissues were lower than normal tissues (p-value < 0.05). -
Emerging Roles of Metallothioneins in Beta Cell Pathophysiology: Beyond and Above Metal Homeostasis and Antioxidant Response
biology Review Emerging Roles of Metallothioneins in Beta Cell Pathophysiology: Beyond and above Metal Homeostasis and Antioxidant Response Mohammed Bensellam 1,* , D. Ross Laybutt 2,3 and Jean-Christophe Jonas 1 1 Pôle D’endocrinologie, Diabète et Nutrition, Institut de Recherche Expérimentale et Clinique, Université Catholique de Louvain, B-1200 Brussels, Belgium; [email protected] 2 Garvan Institute of Medical Research, Sydney, NSW 2010, Australia; [email protected] 3 St Vincent’s Clinical School, UNSW Sydney, Sydney, NSW 2010, Australia * Correspondence: [email protected]; Tel.: +32-2764-9586 Simple Summary: Defective insulin secretion by pancreatic beta cells is key for the development of type 2 diabetes but the precise mechanisms involved are poorly understood. Metallothioneins are metal binding proteins whose precise biological roles have not been fully characterized. Available evidence indicated that Metallothioneins are protective cellular effectors involved in heavy metal detoxification, metal ion homeostasis and antioxidant defense. This concept has however been challenged by emerging evidence in different medical research fields revealing novel negative roles of Metallothioneins, including in the context of diabetes. In this review, we gather and analyze the available knowledge regarding the complex roles of Metallothioneins in pancreatic beta cell biology and insulin secretion. We comprehensively analyze the evidence showing positive effects Citation: Bensellam, M.; Laybutt, of Metallothioneins on beta cell function and survival as well as the emerging evidence revealing D.R.; Jonas, J.-C. Emerging Roles of negative effects and discuss the possible underlying mechanisms. We expose in parallel findings Metallothioneins in Beta Cell from other medical research fields and underscore unsettled questions. -
WO 2014/135655 Al 12 September 2014 (12.09.2014) P O P C T
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/135655 Al 12 September 2014 (12.09.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/EP2014/054384 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 6 March 2014 (06.03.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 13305253.0 6 March 2013 (06.03.2013) EP (84) Designated States (unless otherwise indicated, for every (71) Applicants: INSTITUT CURIE [FR/FR]; 26 rue d'Ulm, kind of regional protection available): ARIPO (BW, GH, F-75248 Paris cedex 05 (FR). CENTRE NATIONAL DE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, LA RECHERCHE SCIENTIFIQUE [FR/FR]; 3 rue UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, Michel Ange, F-75016 Paris (FR). -
Investigation of the Underlying Hub Genes and Molexular Pathogensis in Gastric Cancer by Integrated Bioinformatic Analyses
bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Investigation of the underlying hub genes and molexular pathogensis in gastric cancer by integrated bioinformatic analyses Basavaraj Vastrad1, Chanabasayya Vastrad*2 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.20.423656; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The high mortality rate of gastric cancer (GC) is in part due to the absence of initial disclosure of its biomarkers. The recognition of important genes associated in GC is therefore recommended to advance clinical prognosis, diagnosis and and treatment outcomes. The current investigation used the microarray dataset GSE113255 RNA seq data from the Gene Expression Omnibus database to diagnose differentially expressed genes (DEGs). Pathway and gene ontology enrichment analyses were performed, and a proteinprotein interaction network, modules, target genes - miRNA regulatory network and target genes - TF regulatory network were constructed and analyzed. Finally, validation of hub genes was performed. The 1008 DEGs identified consisted of 505 up regulated genes and 503 down regulated genes. -
A Comparative Genomic Study in Schizophrenic and in Bipolar Disorder Patients, Based on Microarray Expression Pro�Ling Meta�Analysis
Hindawi Publishing Corporation e Scienti�c �orld �ournal Volume 2013, Article ID 685917, 14 pages http://dx.doi.org/10.1155/2013/685917 Research Article A Comparative Genomic Study in Schizophrenic and in Bipolar Disorder Patients, Based on Microarray Expression Pro�ling Meta�Analysis Marianthi Logotheti,1, 2, 3 Olga Papadodima,2 Nikolaos Venizelos,1 Aristotelis Chatziioannou,2 and Fragiskos Kolisis3 1 Neuropsychiatric Research Laboratory, Department of Clinical Medicine, Örebro University, 701 82 Örebro, Sweden 2 Metabolic Engineering and Bioinformatics Program, Institute of Biology, Medicinal Chemistry and Biotechnology, National Hellenic Research Foundation, 48 Vassileos Constantinou Avenue, 11635 Athens, Greece 3 Laboratory of Biotechnology, School of Chemical Engineering, National Technical University of Athens, 15780 Athens, Greece Correspondence should be addressed to Aristotelis Chatziioannou; [email protected] and Fragiskos Kolisis; [email protected] Received 2 November 2012; Accepted 27 November 2012 Academic Editors: N. S. T. Hirata, M. A. Kon, and K. Najarian Copyright © 2013 Marianthi Logotheti et al. is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Schizophrenia affecting almost 1 and bipolar disorder affecting almost 3 –5 of the global population constitute two severe mental disorders. e catecholaminergic and the serotonergic pathways have been proved to play an important role in the development of schizophrenia, bipolar% disorder, and other related psychiatric% disorders.% e aim of the study was to perform and interpret the results of a comparative genomic pro�ling study in schizophrenic patients as well as in healthy controls and in patients with bipolar disorder and try to relate and integrate our results with an aberrant amino acid transport through cell membranes. -
Differences in TCDD-Elicited Gene Expression Profiles in Human
Dere et al. BMC Genomics 2011, 12:193 http://www.biomedcentral.com/1471-2164/12/193 RESEARCHARTICLE Open Access Differences in TCDD-elicited gene expression profiles in human HepG2, mouse Hepa1c1c7 and rat H4IIE hepatoma cells Edward Dere1, Andrea W Lee1, Lyle D Burgoon1,2 and Timothy R Zacharewski1,2* Abstract Background: 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is an environmental contaminant that elicits a broad spectrum of toxic effects in a species-specific manner. Current risk assessment practices routinely extrapolate results from in vivo and in vitro rodent models to assess human risk. In order to further investigate the species-specific responses elicited by TCDD, temporal gene expression responses in human HepG2, mouse Hepa1c1c7 and rat H4IIE cells were compared. Results: Microarray analysis identified a core set of conserved gene expression responses across species consistent with the role of AhR in mediating adaptive metabolic responses. However, significant species-specific as well as species-divergent responses were identified. Computational analysis of the regulatory regions of species-specific and -divergent responses suggests that dioxin response elements (DREs) are involved. These results are consistent with in vivo rat vs. mouse species-specific differential gene expression, and more comprehensive comparative DRE searches. Conclusions: Comparative analysis of human HepG2, mouse Hepa1c1c7 and rat H4IIE TCDD-elicited gene expression responses is consistent with in vivo rat-mouse comparative gene expression studies, and more comprehensive comparative DRE searches, suggesting that AhR-mediated gene expression is species-specific. Background downstream physiological responses [3]. Although the 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiqui- structure and function of the AhR are highly conserved tous environmental contaminant that elicits a broad [4], the sensitivity to and the responses elicited by spectrum of biochemical and physiological effects in a TCDD vary widely across species, suggesting TCDD and species-specific manner [1]. -
Establishment of a Novel Human CIC-DUX4 Sarcoma Cell Line, Kitra
www.nature.com/scientificreports Corrected: Author Correction OPEN Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs Sho Nakai1, Shutaro Yamada2, Hidetatsu Outani1, Takaaki Nakai3, Naohiro Yasuda1, Hirokazu Mae1, Yoshinori Imura4, Toru Wakamatsu4, Hironari Tamiya4, Takaaki Tanaka4, Kenichiro Hamada1, Akiyoshi Tani5, Akira Myoui1, Nobuhito Araki6, Takafumi Ueda7, Hideki Yoshikawa1, Satoshi Takenaka1* & Norifumi Naka1,4 Approximately 60–70% of EWSR1-negative small blue round cell sarcomas harbour a rearrangement of CIC, most commonly CIC-DUX4. CIC-DUX4 sarcoma (CDS) is an aggressive and often fatal high-grade sarcoma appearing predominantly in children and young adults. Although cell lines and their xenograft models are essential tools for basic research and development of antitumour drugs, few cell lines currently exist for CDS. We successfully established a novel human CDS cell line designated Kitra-SRS and developed orthotopic tumour xenografts in nude mice. The CIC-DUX4 fusion gene in Kitra-SRS cells was generated by t(12;19) complex chromosomal rearrangements with an insertion of a chromosome segment including a DUX4 pseudogene component. Kitra-SRS xenografts were histologically similar to the original tumour and exhibited metastatic potential to the lungs. Kitra-SRS cells displayed autocrine activation of the insulin-like growth factor 1 (IGF-1)/IGF-1 receptor (IGF-1R) pathway. Accordingly, treatment with the IGF-1R inhibitor, linsitinib, attenuated Kitra-SRS cell growth and IGF-1-induced activation of IGF-1R/AKT signalling both in vitro and in vivo. Furthermore, upon screening 1134 FDA- approved drugs, the responses of Kitra-SRS cells to anticancer drugs appeared to refect those of the primary tumour. -
The Roles of Metallothioneins in Carcinogenesis Manfei Si and Jinghe Lang*
Si and Lang Journal of Hematology & Oncology (2018) 11:107 https://doi.org/10.1186/s13045-018-0645-x REVIEW Open Access The roles of metallothioneins in carcinogenesis Manfei Si and Jinghe Lang* Abstract Metallothioneins (MTs) are small cysteine-rich proteins that play important roles in metal homeostasis and protection against heavy metal toxicity, DNA damage, and oxidative stress. In humans, MTs have four main isoforms (MT1, MT2, MT3, and MT4) that are encoded by genes located on chromosome 16q13. MT1 comprises eight known functional (sub)isoforms (MT1A, MT1B, MT1E, MT1F, MT1G, MT1H, MT1M, and MT1X). Emerging evidence shows that MTs play a pivotal role in tumor formation, progression, and drug resistance. However, the expression of MTs is not universal in all human tumors and may depend on the type and differentiation status of tumors, as well as other environmental stimuli or gene mutations. More importantly, the differential expression of particular MT isoforms can be utilized for tumor diagnosis and therapy. This review summarizes the recent knowledge on the functions and mechanisms of MTs in carcinogenesis and describes the differential expression and regulation of MT isoforms in various malignant tumors. The roles of MTs in tumor growth, differentiation, angiogenesis, metastasis, microenvironment remodeling, immune escape, and drug resistance are also discussed. Finally, this review highlights the potential of MTs as biomarkers for cancer diagnosis and prognosis and introduces some current applications of targeting MT isoforms in cancer therapy. The knowledge on the MTs may provide new insights for treating cancer and bring hope for the elimination of cancer. Keywords: Metallothionein, Metal homeostasis, Cancer, Carcinogenesis, Biomarker Background [6–10]. -
Loss of CIC Promotes Mitotic Dysregulation and Chromosome Segregation Defects
bioRxiv preprint doi: https://doi.org/10.1101/533323; this version posted January 29, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Loss of CIC promotes mitotic dysregulation and chromosome segregation defects. Suganthi Chittaranjan1, Jungeun Song1, Susanna Y. Chan1, Stephen Dongsoo Lee1, Shiekh Tanveer Ahmad2,3,4, William Brothers1, Richard D. Corbett1, Alessia Gagliardi1, Amy Lum5, Annie Moradian6, Stephen Pleasance1, Robin Coope1, J Gregory Cairncross2,7, Stephen Yip5,8, Emma Laks5,8, Samuel A.J.R. Aparicio5,8, Jennifer A. Chan2,3,4, Christopher S. Hughes1, Gregg B. Morin1,9, Veronique G. LeBlanc1, Marco A. Marra1,9* Affiliations 1 Canada's Michael Smith Genome Sciences Centre, BC Cancer, Vancouver, Canada 2 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada 3 Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, Canada 4 Alberta Children’s Hospital Research Institute, University of Calgary, Calgary, Canada 5 Department of Molecular Oncology, BC Cancer, Vancouver, Canada 6 California Institute of Technology, Pasadena, USA 7 Department of Clinical Neurosciences, University of Calgary, Calgary, Canada 8 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada 9 Department of Medical Genetics, University of British Columbia, Vancouver, Canada Corresponding author Marco A. Marra Genome Sciences Centre BC Cancer 675 West 10th Avenue, Vancouver, BC Canada V5Z 1L3 E-mail: [email protected] 604-675-8162 1 bioRxiv preprint doi: https://doi.org/10.1101/533323; this version posted January 29, 2019. -
The Functions of Metamorphic Metallothioneins in Zinc and Copper Metabolism
International Journal of Molecular Sciences Review The Functions of Metamorphic Metallothioneins in Zinc and Copper Metabolism Artur Kr˛ezel˙ 1 and Wolfgang Maret 2,* 1 Department of Chemical Biology, Faculty of Biotechnology, University of Wrocław, Joliot-Curie 14a, 50-383 Wrocław, Poland; [email protected] 2 Division of Diabetes and Nutritional Sciences, Department of Biochemistry, Faculty of Life Sciences and Medicine, King’s College London, 150 Stamford Street, London SE1 9NH, UK * Correspondence: [email protected]; Tel.: +44-020-7848-4264; Fax: +44-020-7848-4195 Academic Editor: Eva Freisinger Received: 25 April 2017; Accepted: 3 June 2017; Published: 9 June 2017 Abstract: Recent discoveries in zinc biology provide a new platform for discussing the primary physiological functions of mammalian metallothioneins (MTs) and their exquisite zinc-dependent regulation. It is now understood that the control of cellular zinc homeostasis includes buffering of Zn2+ ions at picomolar concentrations, extensive subcellular re-distribution of Zn2+, the loading of exocytotic vesicles with zinc species, and the control of Zn2+ ion signalling. In parallel, characteristic features of human MTs became known: their graded affinities for Zn2+ and the redox activity of their thiolate coordination environments. Unlike the single species that structural models of mammalian MTs describe with a set of seven divalent or eight to twelve monovalent metal ions, MTs are metamorphic. In vivo, they exist as many species differing in redox state and load with different metal ions. The functions of mammalian MTs should no longer be considered elusive or enigmatic because it is now evident that the reactivity and coordination dynamics of MTs with Zn2+ and Cu+ match the biological requirements for controlling—binding and delivering—these cellular metal ions, thus completing a 60-year search for their functions. -
Negative MAPK-ERK Regulation Sustains CIC-DUX4 Oncoprotein Expression in Undifferentiated Sarcoma
Negative MAPK-ERK regulation sustains CIC-DUX4 oncoprotein expression in undifferentiated sarcoma Yone Kawe Lina, Wei Wua,b, Rovingaile Kriska Poncea, Ji Won Kima, and Ross A. Okimotoa,b,c,1 aDivision of Hematology and Oncology, University of California, San Francisco, CA 94143; bHelen Diller Comprehensive Cancer Center, University of California, San Francisco, CA 94115; and cDepartment of Medicine, University of California, San Francisco, CA 94143 Edited by Harold Varmus, Weill Cornell Medical College, New York, NY, and approved July 15, 2020 (received for review May 12, 2020) Transcription factor fusions (TFFs) are present in ∼30% of soft- CIC-DUX4 bearing cell line, NCC_CDS_X1 (6, 13). Using tissue sarcomas. TFFs are not readily “druggable” in a direct phar- model-based analysis for ChIP-seq (MACS) (14, 15), we identi- macologic manner and thus have proven difficult to target in the fied 260 CIC-DUX4 binding peaks present at a high level of clinic. A prime example is the CIC-DUX4 oncoprotein, which fuses significance (P < 0.05 and false discovery rate [FDR] <0.01) Capicua (CIC) to the double homeobox 4 gene, DUX4. CIC-DUX4 (Fig. 1A). Eighty-two percent of the binding peaks were located sarcoma is a highly aggressive and lethal subtype of small round in either intergenic (43%) or intronic (39%) sites, and 12% were cell sarcoma found predominantly in adolescents and young within 3 kb of the transcriptional start site (TSS), defined as the adults. To identify new therapeutic targets in CIC-DUX4 sarcoma, promoter region (Fig. 1B). Among the genes identified were we performed chromatin immunoprecipitation sequencing analy- known CIC-DUX4 targets including ETV1, ETV4, and ETV5 sis using patient-derived CIC-DUX4 cells.